Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib (HL-085) and Vemurafenib in Metastatic Colorectal Cancer
NCT05233332Phase 2Unknown
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tunlametinib in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoints: Objective Response Rate at 12 months and Objective Response Rate (Independent Central Review) at 12 months. Status: unknown.
02
Drugs
tunlametinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05233332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233332.